SEER program

SEER program
Name	SEER program
Established	1973
Owner	National Cancer Institute
Country	United States

SEER program

The SEER program is a United States national cancer surveillance system administered by the National Cancer Institute. It collects incidence, survival, and prevalence data about malignant and selected benign tumors from population-based cancer registries, informing public health policy, clinical research, and epidemiology. Data from the program are integrated with population demographics, staging systems, and mortality statistics to support analyses by clinicians, researchers, and policymakers.

Overview

The program compiles data from multiple cancer registries such as the Connecticut Department of Public Health, Los Angeles County Cancer Surveillance Program, New Jersey State Cancer Registry, Hawaii Tumor Registry, and Atlanta Metropolitan Tumor Registry, covering diverse populations including residents of California, New York, Texas, Florida, and Washington. It uses classification systems developed by organizations like the American Joint Committee on Cancer, the World Health Organization, and the International Classification of Diseases for Oncology to code tumor sites and morphology. The program's datasets are linked with mortality files from the National Center for Health Statistics and demographic estimates from the U.S. Census Bureau, enabling comparisons with data from the Centers for Disease Control and Prevention, Veterans Health Administration, and academic centers such as Johns Hopkins Hospital and Mayo Clinic.

History

The program was established in 1973 following initiatives by the National Cancer Act of 1971 and in collaboration with state and regional registries including those in Iowa, New Mexico, and Georgia. Early partnerships involved institutions like Harvard School of Public Health, University of Michigan School of Public Health, and University of Southern California to expand coverage and standardize reporting. Over decades the program adopted staging revisions from the American Joint Committee on Cancer and coding updates from the International Agency for Research on Cancer, while integrating electronic reporting linked to health information systems used at centers such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.

Methodology and Data Collection

Case ascertainment is performed through active and passive reporting from hospitals, pathology laboratories, and outpatient clinics including networks affiliated with Kaiser Permanente, Montefiore Medical Center, and Cedars-Sinai Medical Center. Registrars use standardized abstraction manuals and software influenced by tools from the North American Association of Central Cancer Registries and coding rules promulgated by the National Program of Cancer Registries. Variables captured include patient demographics, tumor site and histology per the International Classification of Diseases for Oncology, stage defined by the American Joint Committee on Cancer staging manuals, first course of treatment, and follow-up vital status cross-checked against the National Death Index. Quality control measures reference methodologies from the U.S. Preventive Services Task Force and auditing practices used by institutions like Centers for Medicare & Medicaid Services.

Major Findings and Impact

Analyses using the program have documented trends in incidence and survival for malignancies such as breast cancer, lung cancer, prostate cancer, colorectal cancer, and melanoma. Studies leveraging the data have informed screening guidelines endorsed by bodies including the U.S. Preventive Services Task Force and have influenced policy deliberations in the Department of Health and Human Services and at the White House. Research published by investigators at Harvard Medical School, Stanford University School of Medicine, Yale School of Medicine, and University of California, San Francisco has used the data to evaluate disparities by race/ethnicity among groups identified in census categories, geographic variation across states like Arizona and Louisiana, and survival improvements following therapeutic advances introduced at centers such as Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute.

Limitations and Criticisms

Critiques have highlighted issues including under-ascertainment in rural areas such as parts of Alaska and Mississippi, latency in data release relative to rapid clinical advances at hospitals like Cleveland Clinic and Brigham and Women's Hospital, and limited granularity for treatment details compared with clinical trial datasets from organizations like the National Comprehensive Cancer Network. Methodological concerns raised by researchers at Columbia University Irving Medical Center and University of Pennsylvania Health System include coding inconsistencies when staging systems change, potential misclassification across demographic groups, and challenges in linking to molecular datasets generated at institutions such as Broad Institute and Sanger Institute.

Accessibility and Use in Research

Public-use datasets are distributed with de-identified records for investigators from universities such as University of California, Los Angeles and University of Chicago, while restricted-use files are available under agreements for linkage with administrative data from systems like Medicare and the Social Security Administration. Training and software tools for registry staff are provided in collaboration with the North American Association of Central Cancer Registries and academic partners including University of Iowa. The program supports workshops and publications used by analysts at National Institutes of Health, private research firms, and nonprofit organizations such as the American Cancer Society to generate peer-reviewed studies and policy reports.

Category:Cancer registries